• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Cannabis

CannTrust Is Caught in a Cannabis Catch-22

The loss of clients is a primary concern here.
By TIMOTHY COLLINS
Jul 12, 2019 | 01:00 PM EDT
Stocks quotes in this article: CTST

CannTrust (CTST) is looking more like "Can't Trust" this week.

When news about the Canadian cannabis name broke this week, I reached out to the company on Wednesday (no response) and followed-up on Thursday, which generated a call from their PR firm. In less than a minute, it became clear to me that CannTrust is caught in the same Catch-22 many spiraling companies find themselves, especially when dealing with regulators or quiet periods: they simply can't say anything.

Let's do a very quick recap.

On July 8, the company announced it received a notice from regulator Health Canada that its greenhouse facility in Pelham, Ontario was not in compliance. Between October 2018 and March 2019, the company produced cannabis in five unlicensed grow rooms. Health Canada placed a hold on 5,200 kg of dried cannabis harvested from these rooms and CannTrust placed a voluntary hold on another 7,500 kg of dried cannabis previously produced in those rooms.

By the end of the day on July 9, CannTrust shares received four downgrades and a slew of law firms announcing an investigation with the intent of filing a class action lawsuit.

On Thursday, a report from The Globe & Mail hits. According to a whistleblower, Health Canada would have never known what to look for had he not tipped them off. The potential devastating portion of the email outlines how a manager at the facility allegedly instructed the whistleblower to help erect fake walls to conceal the illegal growing.

After the close Thursday, CannTrust announced it has implemented a "voluntary" hold on the sale and shipment of all cannabis products as a "precaution" while Health Canada reviews the Vaughan, Ontario manufacturing facility. It also formed a Special Committee of the Board of Directors to investigate the matter.

As a reminder, current CEO Peter Aceto, accepted that role on Oct. 1, 2018.

There's a lot to unpack here.

With Aceto just coming into his role at the beginning of October, it would be a bold move for a brand-new CEO to institute allegedly illegal growing as one of their first acts in leadership. Given the challenges associated with obtaining Pelham approval, I have a difficult time believing Aceto had any knowledge initially. It's likely he had no knowledge at all. But is that a good thing? Does it give the picture of a CEO out of touch or one "protected" by those in the know?

These are all personal opinions and none of the answers are good ones, but my belief is Aceto did not know. Whether he has a position with CannTrust after all this is another story.

The challenge for investors is they are going to hear rumors and the company can't really respond. By responding, they risk violating any potential discussions they've had with Health Canada (or even irritating Health Canada). By not responding, we'll likely hear rumors of suspended licenses or the company having their license revoked.

While the rumors may come to fruition, the loss of clients is my primary concern. As of March 31, 2019, the company had 68,000 medical cannabis patients. If this hold on product sales continues for too long, those patients are going to seek product elsewhere and chances of CannTrust getting them back will significantly decrease each day that passes.

Furthermore, in early May, the company sold 36.36 million shares at $5.50 per share in a secondary offering. Given the timing of the illegal growing, one has to worry about a clawback. That's a major concern here.

While I would love to scoop up a cheap stock on an overreaction, there are too many flags here. Yellow flags, red flags, white flags of surrender, black flags of death, and just about every other negative color imaginable.

Until we have more clarity, if you want to be involved in the space, I'd take advantage of the widespread carnage in the space we're seeing because of CannTrust. That is, as long as you have patience.

There's no telling how deep the selloff could run, so I would ease into names. It's definitely ugly out there.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins had no positions in any securities mentioned.

TAGS: Regulation | Litigation | Investing | Trading | Cannabis

More from Cannabis

Doug Kass: Cannabis Stocks Are Still Not SAFE

Doug Kass
Dec 20, 2022 11:15 AM EST

Though it is tempting, there are a host of reasons why I'm not bottom fishing.

Cannabis ETFs Could Soon Turn a New Leaf

Mark Abssy
Dec 8, 2022 1:11 PM EST

With likely passage of new legislation, the pot industry might have a remedy for the nausea it gave investors.

3 Market Sectors Are Likely to Be Most Impacted by the Midterm Election

James "Rev Shark" DePorre
Nov 8, 2022 6:22 AM EST

The focus is on positioning for the election and CPI Thursday.

I'm Monitoring a Cannabis ETF That's Showing Signs of Bottoming

Bob Byrne
Nov 7, 2022 8:04 AM EST

It's a dicey play as the price action isn't defined as yet and the ETF still could break lower.

If You're High on Tilray, Invest for the Long Term

Stephen Guilfoyle
Oct 7, 2022 11:06 AM EDT

TLRY is probably not that close to sustained profitability, but it has built the balance sheet to tough out these hard times.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • 05:00 PM EDT CHRIS VERSACE

    AAP Podcast on the Fed Decision!

    Listen here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login